Beyond asthma, GERD was also identified as a predictor of biologic use, possibly relating to increased likelihood of type 2 inflammation (i.e., eosinophilia and high levels of interleukin-4/5/13) and therefore biologic selection, in patients with CRSwNP and GERD [7, 8, 42]. The gene discussed is IL4; the disease is gastroesophageal reflux disease.